UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

July 21, 2005
(Date of earliest event reported)

LABORATORY CORPORATION OF
AMERICA HOLDINGS

(Exact Name of Registrant as Specified in its Charter)


DELAWARE	1-11353	13-3757370

(State or other jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)


358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA	27215	336-229-1127

(Address of principal executive offices)	(Zip Code)	(Registrant's telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01. Regulation FD Disclosure

Summary information of the Company dated July 21, 2005.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	Laboratory Corporation of America Holdings (Registrant)
Date: July 21, 2005	By:	/s/Bradford T. Smith
		Bradford T. Smith, Executive Vice President and Secretary

8-K Filed July 21, 2005

This slide presentation contains forward-looking
statements which are subject to change based on
various important factors, including without
limitation, competitive actions in the marketplace and
adverse actions of governmental and other third-
party payors. Actual results could differ materially
from those suggested by these forward-looking
statements. Further information on potential factors
that could affect the Company’s financial results is
included in the Company’s Form 10-K for the year
ended December 31, 2004, and subsequent filings.

The Clinical Laboratory Testing
Market - $40 billion Annually

Independent clinical lab share
is $16 billion

Represents 2% to 3% of all
health care spending

Influences /directs
approximately 80% of health
care spending

Rapidly evolving technology,
emphasis on preventative
medicine and aging of
population are all driving
growth

Has grown at a CAGR of
between 5% and 6%

Source: Company estimates, industry reports and 2004 revenue for LabCorp.

Profile of LabCorp

A leader in the esoteric and genomic testing
market and second-largest clinical laboratory
company in North America

Offers a broad range of routine and
esoteric/genomic tests

Conducts testing on more than 360,000
specimens daily

Provides lab services to physicians and other
health care providers

Approximately 25,000 employees nationwide

Primary Testing Locations & PSCs

Primary LabCorp Testing Locations

Patient Service Centers

Corporate Headquarters

Burlington, NC

LabCorp’s Investment and
Performance Fundamentals

History of Strong Financial
Performance

Significant Cash Generator

Industry leading EBITDA margins

Strong Balance Sheet

Investment Grade Credit Ratings

Net Sales (in millions)

EBITDA Margin

EPS

Operating Cash Flow (in millions)

(1) Includes approximately $50 million of benefit from one-time tax credits recorded in 2003.

(1)

To lead the industry in achieving
long-term growth and profitability
by strengthening our nationwide
core testing business and
expanding our higher-growth,
higher-value esoteric and
genomic businesses.

LabCorp’s Strategy

Strategic Focus Areas

Scientific

Leadership

Managed

Care

Customer

Retention

-Licensing/partnerships

-Cancer

-Specimen tracking

-Call center consolidation

-Report improvement

-Acquisitions

-Appropriate prices

-Reduce leakage

-Value of new lab tests

-Customer connectivity

Second Quarter Results (in millions, except per share data)

6/30/04

6/30/05

+/(-)

Revenue

$784.3

$853.3

8.8%

EBITDA

(1)

$210.8

$225.2

6.8%

EBITDA Margin

26.9%

26.4%

(50

bp)

Diluted EPS

(2)

$0.66

$0.76

15.2%

(1) For definition of EBITDA and a reconciliation to the most comparable measure under Generally Accepted
Accounting Principles, see Company’s 2nd quarter 2005 earnings release furnished on Form 8-K on July 21, 2005.

(2) Excluding $0.02 per diluted share impact of a non-recurring investment loss.

Six-Month Results (in millions, except per share data)

6/30/04

6/30/05

+/(-)

Revenue

$1,536.8

$1,652.4

7.5%

EBITDA

(1)

$401.9

$432.6

7.6%

EBITDA Margin

26.2%

Diluted EPS

(2)

$1.24

$1.43

15.3%

(2) Excluding a $0.02 per diluted share impact of a non-recurring investment loss.

2005 Six-Month Financial
Achievements

Diluted EPS of $1.43 (1)

EBITDA margin of 26.2% of sales

Operating cash flow of $240.9 million

Increased revenues 7.5% (0.7% volume; 6.8%
price)

Repurchased approximately $122 million of
LabCorp stock

Completed US LABS and Esoterix acquisitions

(1) Excluding a $0.02 per diluted share impact of a non-recurring investment loss.

Financial Performance

Price & Volumes: Trends by Payor Type

Client (Physicians)

Patient

Third Party

(MC/MD/Insurance)

Managed Care

Capitated

Fee for service

Total

LabCorp Total

2003

PPA

Accessions

millions

$27.07

118.48

34.25

9.95

45.68

32.74

$33.43

31.7

2.5

18.1

12.9

22.7

35.6

87.9

2004

PPA

millions

$26.61

123.59

34.84

10.36

46.01

33.67

$33.86

32.7

2.5

18.9

12.8

24.2

37.0

91.1

Accessions

YTD 2005

PPA

millions

$29.18

129.80

37.98

10.31

46.94

34.30

$35.75

15.9

1.2

9.8

6.7

12.6

19.3

46.2

Accessions

Financial Performance

Revenue Analysis by Business Area

YTD JUN 2004

Revenue

% Accns

Accns

PPA

$Million

to total

000

Genomic

Identity/Gene
Probes

All Genomic

Other Esoteric

Histology

All Genomic/
Esoteric

Core

Total

$143.1

1,228.2

2.7%

$116.47

82.5

225.6

144.3

102.6

472.5

1,064.3

$1,536.8

1,884.2

3,112.4

3,497.5

1,128.4

7,738.3

38,155.0

45,893.3

4.1%

6.8%

7.6%

2.5%

16.9%

83.1%

100.0%

43.80

72.48

41.26

90.92

61.06

27.90

$33.49

YTD JUN 2005

Revenue

% Accns

Accns

$Million

to total

000

$164.4

1,401.1

3.1%

$117.32

87.7

252.1

159.4

134.5

546.0

1,106.4

$1,652.4

1,949.3

3,350.4

3,891.6

1,195.2

8,437.2

37,781.4

46,218.6

4.2%

7.3%

8.4%

2.6%

18.3%

81.7%

100.0%

44.98

75.23

40.97

112.53

64.71

29.28

$35.75

PPA

0.7%

2.7%

3.8%

(0.7%)

23.8%

6.0%

5.0%

6.8%

05 vs 04

PPA

Incr/(Decr)

Free Cash Flow Investment
Strategy

Acquisitions

Repayment of revolving line of credit

Stock repurchase program

Retain flexibility in utilizing remaining cash

Updated 2005 Financial Guidance

Revenue growth of approximately 8.5% to 9% compared
to 2004, including in-year revenues of $25 to $35 million
from small acquisitions and/or new contracts

EBITDA margins of 25.5% of revenues

Diluted EPS in the range of $2.75 to $2.80, including the
$0.02 impact of a non-recurring investment loss.

Capital expenditures of between $110 and $125 million

Free cash flow of between $440 and $465 million

Financial Guidance for 2005
(cont’d.)

Net interest expense of approximately $32 million

Bad debt rate of approximately 5.3% of sales for the
remainder of the year

Guidance does not include:

Possible significant contributions from new tests, or

The impact of new accounting for stock based
compensation, or

Any potential restructuring charges as a result of the US
LABS and Esoterix acquisitions.

Other Financial Information

June 30, 2005

Depreciation

Amortization

Capital expenditures

Bad debt as a percentage of sales

23.2

Zero coupon-subordinated notes

Revolving credit facility
(weighted average)

Cash flows from operations

Effective interest rate on debt:

5 1/2% Senior Notes (including
effect of interest rate swap)

Days sales outstanding

YTD
2005

24.1

47.3

12.1

13.1

25.2

25.5

20.2

45.7

154.4

86.5

240.9

5.5%

5.3%

5.4%

2.00%

5.38%

3.31%

3.62%

($ in millions)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549